Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Debt (2016 - 2024)

Capricor Therapeutics has reported Non-Current Debt over the past 12 years, most recently at $3.4 million for Q3 2024.

  • Quarterly results put Non-Current Debt at $3.4 million for Q3 2024, changed 0.0% from a year ago — trailing twelve months through Sep 2024 was $3.4 million (changed 0.0% YoY), and the annual figure for FY2023 was $3.4 million, changed 0.0%.
  • Non-Current Debt for Q3 2024 was $3.4 million at Capricor Therapeutics, roughly flat from $3.4 million in the prior quarter.
  • Over the last five years, Non-Current Debt for CAPR hit a ceiling of $3.4 million in Q1 2020 and a floor of $35469.0 in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $3.4 million (2020), compared with a mean of $2.9 million.
  • Biggest five-year swings in Non-Current Debt: tumbled 98.95% in 2021 and later skyrocketed 9418.9% in 2022.
  • Capricor Therapeutics' Non-Current Debt stood at $3.4 million in 2020, then changed by 0.0% to $3.4 million in 2021, then changed by 0.0% to $3.4 million in 2022, then changed by 0.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024.
  • The last three reported values for Non-Current Debt were $3.4 million (Q3 2024), $3.4 million (Q2 2024), and $3.4 million (Q1 2024) per Business Quant data.